Homepage Top Section1

The Austrian biotech company is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of the MV-LASV Lassa fever vaccine candidate. The phase 1 trial

The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gepotidacin in two studies – EAGLE-1 and EAGLE-2.

Biotoscana is a biopharma group that operates in the Latin American region. The Brazilian company focuses on areas such as oncology and onco-hematology, infectious diseases, and other speciality

As per the terms of the deal, Sartorius Stedim will be acquiring Danaher’s label-free biomolecular characterization, chromatography hardware and resins, and the SoloHill business. The chromatography business is

Achillion is involved in the development of oral small molecule Factor D inhibitors for the treatment of people with complement alternative pathway-mediated rare diseases such as paroxysmal nocturnal

The agreement allows CRISPR, a Swiss gene editing company, to gain access to the KSQ Therapeutics’ intellectual property (IP) for editing certain gene targets in its allogeneic oncology

According to the life sciences company, the technology used by the IonicX XRF Analyzer helps save time and money that is otherwise used on conventional analysis techniques. This

The PEMPHIX trial also showed that MabThera was superior to mycophenolate mofetil (MMF) in the late-stage trial held in adult patients. PEMPHIX has been taken up by Roche

Beovu, which is also known as RTH258, is now the first anti-VEGF to be approved by the regulator. According to Novartis, the drug can offer greater fluid resolution